Genmab has officially opened its new headquarters
The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.
For subscribers
EU lags behind the US and China in artificial intelligence
For subscribers
Edwards Lifesciences subject to unannounced EU inspection
For subscribers
J&J's Darzelex sales disappoint slightly
The US is still the largest market for Darzalex.
Seasoned audio professionals raise USD 1.5m to prepare for production of new hearing aid
At the same time, the Danish hearing aid company Lizn is embarking on a major money round that will bring in USD 8.4m before the end of the year.
For subscribers
Weight loss drug shortage now includes Saxenda
Saxenda will have limited availability in the US through the end of the year.
For subscribers
FTC says settlement talks to resolve blocked Amgen-Horizon deal have ended
The FTC sued over the proposed acquisition in May.
For subscribers
Amplifon lends up to USD 393m for innovation and digitalization
The European Investment Bank is providing millions for, among other things, the digitalization of the treatment of hearing impaired citizens.
For subscribers
Moderna is the world's sixth most innovative company according to Boston Consulting Group
Only tech giants like Apple and Amazon are more innovative than Moderna.
For subscribers
Norway to end reimbursement for Ozempic
Too many patients are receiving Ozempic outside the reimbursement clause in Norway, according to the Norwegian Medicines Agency.
For subscribers
Saniona and AstronauTx partner to discover new treatments of Alzheimer's disease
Collaboration agreement gives British biotech firm AstronauTx access to Saniona’s platform.
For subscribers
FDA will not act on European study of GLP-1 drugs
The European Medicines Agency announced last week that it will investigate GLP-1 drugs for suicide risk. The US counterpart is not planning to follow suit.
For subscribers
Top news from MedWatch this week
News about AGC Biologics, Amgen, Astrazeneca, Coloplast, Demant, Eargo, GN, Horizon, Leo Pharma, Novo Holdings, Novo Nordisk, Radiometer, Sonova and Zealand Pharma.
Competition council forces Coloplast to adjust prices in Denmark
The Danish Competition Council fears that Coloplast is abusing its dominant position to drive competitors out of the market for sales of ostomy products to Danish municipalities.
For subscribers
Musical chairs on the Ferring board: Founder's grandson takes over Lars Rebien's chairmanship
Lars Rebien takes a step down in Ferring’s board of directors.
For subscribers
Chief Development Officer leaves Leo Pharma – internal replacement in place
After a period of uncertainty about the future of Chief Development Officer Jörg Möller, he is now leaving Leo Pharma.
For subscribers
FDA approves cancer drug Epkinly from Genmab and Abbvie
Abbvie and Genmab will jointly market the product in the US.
For subscribers
Ensoma completes purchase of Danish CRISPR firm
US biotech company Ensoma invests millions of kroner in Danish university spin-off following takeover.
For subscribers
GN declared winner of major tender in Australia
The deal runs for five years with an extension option for further five years.
For subscribers
Ambu undertakes major reshuffle, leading to dismissals and departures
Three of eight top executives are leaving Ambu.
For subscribers
Media: FDA to probe accusations of paid weight-loss add in guise of news
US authorities confirm plans to investigate alleged paid ad for Novo Nordisk obesity medication Wegovy in a US TV program. Pharma firm denies accusations.
For subscribers